**FR0000060402 - Common Stock **

Taking everything into account, **ABIO** scores **5** out of 10 in our fundamental rating. **ABIO** was compared to 11 industry peers in the **Independent Power and Renewable Electricity Producers** industry. Both the profitability and the financial health of **ABIO** get a neutral evaluation. Nothing too spectacular is happening here. While showing a medium growth rate, **ABIO** is valued expensive at the moment.

The Piotroski-F score of **ABIO** is **6.00**. This is a neutral score and indicates average health and profitability for **ABIO**.

ROA (3.14%) VS Industry: 100% outperformed.

-120.00

3.14

ROE (11.73%) VS Industry: 71% outperformed.

0.35

20.89

Profit Margin (10.3%) VS Industry: 44% outperformed.

-4.61

27.38

When comparing the current price to the book value of **ABIO**, we can conclude it is valued correctly. It is trading at **3.21** times its book value.

Compared to an average industry **Enterprise Value to EBITDA** ratio of 11.89, **ABIO** is valued in line with its industry peers.

With a **Price/Earnings Ratio** of **27.31**, **ABIO** can be considered very expensive at the moment.

With a **Forward Price/Earnings Ratio** of **26.75**, **ABIO** is valued very expensively.

The high **PEG Ratio**, which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.

Compared to an average industry price book ratio of 3.14, **ABIO** is valued more expensive than its industry peers.

Price/Earnings (27.31) VS Industry: 83% outperformed.

105.26

13.55

Price/Book (3.21) VS Industry: 40% outperformed.

38.41

1.90

Enterprise Value/ EBITDA (11.89) VS Industry: 50% outperformed.

21.28

5.76

Measured over the past 5 years, **ABIO** shows a quite strong growth in **Earnings Per Share**. The EPS has been growing by **10.59%** on average per year.

The **Revenue** has grown by **13.13%** in the past year. This is quite good.

Based on estimates for the next 5 years, **ABIO** will show a small growth in **Earnings Per Share**. The EPS will grow by **7.58%** on average per year.

The **Revenue** has been growing slightly by **9.28%** on average over the past 5 years.

Based on estimates for the next 5 years, **ABIO** will show a small growth in **Revenue**. The Revenue will grow by **6.22%** on average per year.

The EPS growth is decreasing: in the next 5 years the growth will be less than in the last years.

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming 5 years, we see that the growth is decreasing.

Past | Future | ||||||
---|---|---|---|---|---|---|---|

5Y | 3Y | 1Y | 1Y | 2Y | 3Y | 5Y | |

EPS | 10.59% | 8.33% | 6.41% | 3.15% | 10.38% | 7.07% | 7.58% |

Revenue | 9.28% | 10.21% | 13.13% | 8.28% | 6.4% | 6.91% | 6.22% |

The Current Ratio of **ABIO** is much better than the industry average of **1.00**.

A Current Ratio of **1.17** indicates that **ABIO** should not have too much problems paying its short term obligations.

The Piotroski-F score of **ABIO** is **6.00**. This is a neutral score and indicates average health and profitability for **ABIO**.

When comparing the Quick Ratio of **ABIO** to the average industry Current Ratio of **0.90**, **ABIO** is less able to pay its short term obligations than its industry peers.

When comparing the Debt to Equity Ratio of **ABIO** to the average industry Debt to Equity Ratio of **1.31**, **ABIO** required more debt to finance its operations than its industry peers.

Debt/Equity (1.79) VS Industry: 30% outperformed.

2.57

0.00

Quick Ratio (0.89) VS Industry: 30% outperformed.

0.33

15.89

Current Ratio (1.17) VS Industry: 70% outperformed.

0.33

15.94

Altman-Z (1.61) VS Industry: 100% outperformed.

-212.84

1.61

Compared to an average industry **Dividend Yield** of **1.50**, **ABIO** pays a bit more dividend than its industry peers.

On average, the dividend of **ABIO** grows each year by **8.92%**, which is quite nice.

With a **Yearly Dividend Yield** of **1.68%**, **ABIO** has a reasonable but not impressive dividend return.

The dividend of **ABIO** is growing around the same rate as the earnings are growing. If this keeps up the dividend growth is sustainable.

Dividend Yield (1.68%) VS Industry: 66% outperformed.

0.26

2.50

EPA:ABIO (5/27/2022, 5:29:49 PM)**+0.14 (+0.28%) **

GICS Sector | Utilities | ||

GICS IndustryGroup | Utilities | ||

GICS Industry | Independent Power and Renewable Electricity Producers | ||

Earnings (Last) | N/A N/A | Earnings (Next) | N/A N/A |

Ins Owners | N/A | Inst Owners | N/A |

Market Cap | 1.61B | Analysts | 80 |

PE | 27.31 | Fwd PE | 26.75 |

PEG (NY) | 8.66 | PEG (5Y) | 2.58 |

P/S | 2.82 | P/B | 3.21 |

EV/EBITDA | 11.89 |

ROA | 3.14% | ROE | 11.73% |

PM | 10.3 | Asset Turnover | 0.31 |

EPS 1Y | 6.41% | EPS 3Y | 8.33% |

EPS 5Y | 10.59% | EPS growth Q2Q | 16.36% |

EPS Next Y | 3.15% | EPS Next 2Y | 10.38% |

EPS Next 3Y | 7.07% | EPS Next 5Y | 7.58% |

Revenue growth 1Y | 13.13% | Revenue growth 3Y | 10.21% |

Revenue growth 5Y | 9.28% | Revenue growth Q2Q | 19.37% |

Revenue Next Year | 8.28% | Revenue Next 2Y | 6.4% |

Revenue Next 3Y | 6.91% | Revenue Next 5Y | 6.22% |

Current Ratio | 1.17 | Quick Ratio | 0.89 |

Altman-Z | 1.61 | F-Score | 6 |

Debt/Equity | 1.79 |

Dividend Yield | 1.68% | Dividend Growth | 8.92% |

DP | 31.21% | Ex-Date | N/A |

*Find stocks with similar Fundamental rating on the EuroNext*

*Find the competitors with the best fundamentals on the EuroNext*

*Find the competitors with the best valuation on the EuroNext*

*Find the competitors with the best dividend on the EuroNext*